Open Access

REVIEW

Drug discovery in advanced and recurrent endometrial cancer: Recent advances

ALEX A. FRANCOEUR^*, NATALIE AYOUB, DANIELLE GREENBERG, KRISHNANSU S. TEWARI

Department of Obstetrics and Gynecology, University of California, Irvine, Orange, CA 92868, USA

* Corresponding Author: ALEX A. FRANCOEUR. Email:

Oncology Research 2025, 33(7), 1511-1530. https://doi.org/10.32604/or.2025.061120

Received 18 November 2024; Accepted 03 April 2025; Issue published 26 June 2025

Abstract

Endometrial cancer is the most common gynecologic cancer diagnosed in the United States and mortality is on the rise. Advanced and recurrent endometrial cancer represents a treatment challenge as historically there have been limited therapeutic options for patients. In the last several years, multiple practice-changing clinical trials have led to significant improvements in the treatment landscape. This review will cover updates in the treatment and management of advanced and recurrent endometrial cancer with a focus on novel therapeutics, such as anti-PD-L1 and PD-1 inhibitors, poly ADP-ribose polymerase (PARP) inhibitors, antibody-drug conjugates, and hormonal therapy.

---

Keywords

---